Neurologic Adverse Events of Cancer Immunotherapy

Overview

Journal Arq Neuropsiquiatr

Publisher Thieme

Specialties Neurology
Psychiatry

Date 2022 Aug 17

PMID 35976306

Authors

Marcelo Houat de Brito

Affiliations

Soon will be listed here.

Abstract

Cancer immunotherapy encompasses a wide range of treatment modalities that harness the anti-tumor effects of the immune system and have revolutionized oncological treatment in recent years, with approval for its use in more and more cancers. However, it is not without side effects. Several neurological adverse events have been recognized associated with immune checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T-cell therapy, the two main classes of cancer immunotherapy. With the increase in the prevalence of oncological diseases and this type of therapy, it is improbable that neurologists, oncologists, hematologists, and other healthcare professionals who deal with cancer patients will not encounter this type of neurologic complication in their practice in the following years. This article aims to review the epidemiology, clinical manifestations, diagnosis, and management of neurological complications associated with ICI and CAR T-cell therapy.

Citing Articles

Immunotherapy Combined with Radiation in Malignant Melanoma without BRAF Mutations Brain Metastases-Favorable Response after Immunotherapy Continued beyond Progression.

Rahnea-Nita R, Rebegea L, Toma R, Mocanu H, Soare I, Mihailov R J Pers Med. 2024; 14(1).

PMID: 38248787 PMC: 10817469. DOI: 10.3390/jpm14010086.

References

Shi S, Jaoube J, Kanwar R, Jin M, Amorin A, Varanasi V . Neurological adverse effects due to programmed death 1 (PD-1) inhibitors. J Neurooncol. 2020; 148(2):291-297. DOI: 10.1007/s11060-020-03514-8. View

Yamout B, Al Khawajah M . Radiologically isolated syndrome and multiple sclerosis. Mult Scler Relat Disord. 2017; 17:234-237. DOI: 10.1016/j.msard.2017.08.016. View

Dalmau J, Rosenfeld M . Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008; 7(4):327-40. PMC: 2367117. DOI: 10.1016/S1474-4422(08)70060-7. View

Neill L, Rees J, Roddie C . Neurotoxicity-CAR T-cell therapy: what the neurologist needs to know. Pract Neurol. 2020; 20(4):285-293. DOI: 10.1136/practneurol-2020-002550. View

Lazaridis K, Tzartos S . Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front Immunol. 2020; 11:212. PMC: 7033452. DOI: 10.3389/fimmu.2020.00212. View

Santomasso B, Bachier C, Westin J, Rezvani K, Shpall E . The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. Am Soc Clin Oncol Educ Book. 2019; 39:433-444. DOI: 10.1200/EDBK_238691. View

Abboud H, Probasco J, Irani S, Ances B, Benavides D, Bradshaw M . Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. J Neurol Neurosurg Psychiatry. 2021; . PMC: 8292591. DOI: 10.1136/jnnp-2020-325302. View

Abboud H, Probasco J, Irani S, Ances B, Benavides D, Bradshaw M . Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021; 92(7):757-768. PMC: 8223680. DOI: 10.1136/jnnp-2020-325300. View

Vogrig A, Fouret M, Joubert B, Picard G, Rogemond V, Pinto A . Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. 2019; 6(6). PMC: 6705619. DOI: 10.1212/NXI.0000000000000604. View

10.

Guo C, Jiang S, Kuang Y, Hu H . Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis. J Cancer. 2019; 10(1):120-130. PMC: 6329845. DOI: 10.7150/jca.28120. View

11.

Kolb N, Trevino C, Waheed W, Sobhani F, Landry K, Thomas A . Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve. 2018; . DOI: 10.1002/mus.26070. View

12.

Soror N, Hemrock L, Shah P, Loges R, Tharu B . Brain Stem Encephalitis in a Patient With Recurrent Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor: Case Presentation and Review of the Literature. Cureus. 2021; 13(1):e13034. PMC: 7924812. DOI: 10.7759/cureus.13034. View

13.

Haanen J, Carbonnel F, Robert C, Kerr K, Peters S, Larkin J . Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv119-iv142. DOI: 10.1093/annonc/mdx225. View

14.

Rubin D, Danish H, Ali A, Li K, LaRose S, Monk A . Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 2019; 142(5):1334-1348. DOI: 10.1093/brain/awz053. View

15.

. First-Ever CAR T-cell Therapy Approved in U.S. Cancer Discov. 2017; 7(10):OF1. DOI: 10.1158/2159-8290.CD-NB2017-126. View

16.

Jordan B, Benesova K, Hassel J, Wick W, Jordan K . How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors. ESMO Open. 2021; 6(6):100317. PMC: 8637479. DOI: 10.1016/j.esmoop.2021.100317. View

17.

Golnik K, Pena R, Lee A, Eggenberger E . An ice test for the diagnosis of myasthenia gravis. Ophthalmology. 1999; 106(7):1282-6. DOI: 10.1016/S0161-6420(99)00709-5. View

18.

June C, Sadelain M . Chimeric Antigen Receptor Therapy. N Engl J Med. 2018; 379(1):64-73. PMC: 7433347. DOI: 10.1056/NEJMra1706169. View

19.

Moreira A, Loquai C, Pfohler C, Kahler K, Knauss S, Heppt M . Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer. 2018; 106:12-23. DOI: 10.1016/j.ejca.2018.09.033. View

20.

Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J . Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer. 2017; 73:1-8. DOI: 10.1016/j.ejca.2016.12.001. View